Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31520480 | 0.86 | ALDH1A1 (0.50) | ALDH1A1LMNAKDM4EHTTKMT2A | |
| SCHEMBL15966080 | 0.85 | L3MBTL1 (0.62) | HRH4ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL13905030 | 0.85 | HTT (0.57) | ALDH1A1HTTKMT2AMEN1TSHR | |
| SCHEMBL14899243 | 0.84 | HTT (0.71) | ALDH1A1LMNAHTTHSD11B1KMT2A | |
| SCHEMBL18284787 | 0.81 | RXFP1 (0.62) | HRH4ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL31520500 | 0.81 | RXFP1 (0.62) | HRH4ALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL13347722 | 0.81 | ALDH1A1 (0.69) | ALDH1A1LMNAHTTKMT2AMEN1 | |
| SCHEMBL12305558 | 0.80 | HSD11B1 (0.49) | HRH4ALDH1A1LMNAKDM4EHTT | |
| SCHEMBL15966084 | 0.80 | KMT2A (0.68) | HRH4ALDH1A1KDM4EHTTKMT2A | |
| SCHEMBL12859460 | 0.79 | ACHE (0.59) | ALDH1A1KDM4EKMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | HRH4 4708/4885ALDH1A1 1869/4885LMNA 1829/4885 |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | HRH4 2415/4885ALDH1A1 820/4885LMNA 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.